Management of bilateral idiopathic renal hematuria in a dog with silver nitrate

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
The Canadian veterinary journal. La revue vétérinaire canadienne

Publisher Rights Statement:
Copyright and/or publishing rights held by the Canadian Veterinary Medical Association

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Management of bilateral idiopathic renal hematuria in a dog with silver nitrate

Michael F. Di Cicco, Tara Fetzer, Patricia L. Secoura, Kieri Jermyn, Tracy Hill, Serge Chaloub, Shelly Vaden

Abstract — Renal hematuria has limited treatment options. This report describes management of bilateral idiopathic renal hematuria in a dog with surgically assisted installation of 0.5% silver nitrate solution. Initial treatment resulted in freedom from clinical signs or recurrent anemia for 10 months; however, recurrence of bleeding following a nephrectomy resulted in euthanasia.

Résumé — Gestion de l’hématurie rénale idiopathique bilatérale chez un chien à l’aide du nitrate d’argent. L’hématurie rénale offre des options de traitement limitées. Ce rapport décrit la gestion de l’hématurie rénale idiopathique bilatérale chez un chien à l’aide de l’installation assistée par chirurgie d’une solution de nitrate d’argent de 0,5 %. Le traitement initial a produit une disparition des signes cliniques ou de l’anémie récurrente pendant 10 mois. Cependant, la récurrence des saignements après une néphrectomie se sont traduits par l’euthanasie.

Can Vet J 2013;54:761–764

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013

Di Cicco et al. 2013
contained layered hyperechoic material consistent with blood clots. Both kidneys contained small cortical cysts, and had normal vasculature and flow; kidney sizes were within the reference range (RR: 3.2 cm to 6.4 cm for dogs weighing 5 to 14 kg). Three-view thoracic radiographs were normal. The dog received a packed red blood cell (pRBC) transfusion (10 mL/kg BW over 3 h) without complication. Twelve hours after transfusion the packed cell volume (PCV) and total solids (TS) were 30% (RR: 39% to 53%) and 60 g/L (RR: 60 to 80 g/dL), respectively.

The following day cystoscopy (using a 2.1 mm rigid Karl Storz cystoscope) was performed while the dog was anesthetized and pre-anesthesia medication included hydromorphone (Hydromorphone HCl; Baxter Healthcare, Deerfield, Illinois, USA), 0.1 mg/kg body weight (BW), IM; induction with propofol (Propofol; Abbott Laboratories, North Chicago, Illinois, USA), 6 mg/kg BW, IV; general anesthesia was maintained with inhaled isoflurane (Isoflurane; Piramal Healthcare, Piramal Critical Care, Bethlehem, Pennsylvania, USA) and oxygen.

The ureteral orifices were normal in appearance and clear to yellow jets were visualized from each. The portion of the bladder mucosa that was visualized appeared normal and there was no evidence of overt bleeding, although complete visualization of the entire bladder mucosa was precluded due to the presence of large consolidated blood clots. Because a cause of the severe hemorrhage had not been identified and the large blood clots that were preventing complete visualization of the bladder wall could not be removed during cystoscopy, a second cystotomy was done (9). Several large blood clots were extracted from the urinary bladder and clear urine was visualized from both ureters. The urinary bladder and ureters were grossly normal. A bladder wall biopsy was collected prior to closing in a simple continuous and Cushing’s pattern with 3-0 PDS, and the skin was apposed with adhesive tissue glue (Vetbond Tissue Adhesive; 3M Health Care, Somerville, New Jersey, USA). Bladder wall histopathology revealed mild chronic multifocal mucosal hyperplasia.

Post-operative care included 0.45% NaCl (0.45% NaCl; Abbott Laboratories), 60 mL/kg BW/day, supplemented with potassium chloride (Potassium chloride; Hospira, Lake Forest, Illinois, USA), 0.05 mEq KCl/kg BW/h, fentanyl (Fentanyl; Hospira) continuous rate infusion (CRI), 3 µg/kg BW/h, and amoxicillin-clavulanic acid (Clavamox; Pfizer Animal Health, St. Paul, Minnesota, USA). The following day a transdermal fentanyl patch (50 µg/h) and famotidine (Famotidine; Baxter Healthcare), 1 mg/kg BW, PO, q12h.

The dog was taken to the referring veterinarian 2 d after discharge for malaise, pollakuria, and stranguria with passage of large blood clots. A transdermal fentanyl patch (50 µg/h) and famotidine (Famotidine; Baxter Healthcare), 1 mg/kg BW, PO, q12h.

A repeat CBC disclosed a regenerative anemia (HCT 23.3%, 103,000 reticulocytes), thrombocytosis (469 × 10³/UL, RR: 190 to 468 × 10³/UL), leukocytosis (14.49 × 10³/UL, RR 4.39 to 11.61 × 10³/UL), mature neutrophilia (13.62 × 10³/UL, RR: 2.84 to 9.11 × 10³/UL), and lymphopenia (0.580 × 10³/UL, RR: 0.59 to 3.30 × 10³/UL). A transdermal fentanyl patch (Fentanyl Transdermal System; Corium International, Grand Rapids, Michigan, USA), (50 µg) was placed and iron dextran (Iron Dextran; Phoenix Pharmaceuticals, St. Joseph, Missouri, USA), 10 mg/kg BW, IM, was administered. Prior to discharge the next day the dog was noted to have 1 episode of passage of discolored, red urine. The dog was discharged from the hospital with a presumptive diagnosis of idiopathic renal hematuria and instructions to be given tramadol (Tramadol HCl; Amneal Pharmaceuticals, Glasgow, Kentucky, USA), 2 mg/kg BW, PO, q8h, ferrous sulfate (Ferrous sulfate; Plus Pharma, Commack, New York, New York, USA), 8 mg/kg BW, PO, q24h, amoxicillin-clavulanic acid, a transdermal fentanyl patch (50 µg/h) and famotidine (Famotidine; Baxter Healthcare), 1 mg/kg BW, PO, q12h.

The dog was taken to the referring veterinarian 2 d after discharge with the presumptive diagnosis of idiopathic renal hematuria and instructions to be given tramadol (Tramadol HCl; Amneal Pharmaceuticals, Glasgow, Kentucky, USA), 2 mg/kg BW, PO, q8h, ferrous sulfate (Ferrous sulfate; Plus Pharma, Commack, New York, New York, USA), 8 mg/kg BW, PO, q24h, amoxicillin-clavulanic acid, a transdermal fentanyl patch (50 µg/h) and famotidine (Famotidine; Baxter Healthcare), 1 mg/kg BW, PO, q12h.

A repeat CBC disclosed a regenerative anemia (HCT 23.3%, 103,000 reticulocytes), thrombocytosis (469 × 10³/UL, RR: 190 to 468 × 10³/UL), leukocytosis (14.49 × 10³/UL, RR 4.39 to 11.61 × 10³/UL), mature neutrophilia (13.62 × 10³/UL, RR: 2.84 to 9.11 × 10³/UL), and lymphopenia (0.580 × 10³/UL, RR: 0.59 to 3.30 × 10³/UL). A transdermal fentanyl patch (Fentanyl Transdermal System; Corium International, Grand Rapids, Michigan, USA), (50 µg) was placed and iron dextran (Iron Dextran; Phoenix Pharmaceuticals, St. Joseph, Missouri, USA), 10 mg/kg BW, IM, was administered. Prior to discharge the next day the dog was noted to have 1 episode of passage of discolored, red urine. The dog was discharged from the hospital with a presumptive diagnosis of idiopathic renal hematuria and instructions to be given tramadol (Tramadol HCl; Amneal Pharmaceuticals, Glasgow, Kentucky, USA), 2 mg/kg BW, PO, q8h, ferrous sulfate (Ferrous sulfate; Plus Pharma, Commack, New York, New York, USA), 8 mg/kg BW, PO, q24h, amoxicillin-clavulanic acid, a transdermal fentanyl patch (50 µg/h) and famotidine (Famotidine; Baxter Healthcare), 1 mg/kg BW, PO, q12h.

The dog was taken to the referring veterinarian 2 d after discharge for malaise, pollakuria, and stranguria with passage of large blood clots. A repeat CBC disclosed a regenerative anemia (HCT 23.3%, 103,000 reticulocytes), thrombocytosis (469 × 10³/UL, RR: 190 to 468 × 10³/UL), leukocytosis (14.49 × 10³/UL, RR 4.39 to 11.61 × 10³/UL), mature neutrophilia (13.62 × 10³/UL, RR: 2.84 to 9.11 × 10³/UL), and lymphopenia (0.580 × 10³/UL, RR: 0.59 to 3.30 × 10³/UL). A transdermal fentanyl patch (Fentanyl Transdermal System; Corium International, Grand Rapids, Michigan, USA), (50 µg) was placed and iron dextran (Iron Dextran; Phoenix Pharmaceuticals, St. Joseph, Missouri, USA), 10 mg/kg BW, IM, was administered. Prior to discharge the next day the dog was noted to have 1 episode of passage of discolored, red urine. The dog was discharged from the hospital with a presumptive diagnosis of idiopathic renal hematuria and instructions to be given tramadol (Tramadol HCl; Amneal Pharmaceuticals, Glasgow, Kentucky, USA), 2 mg/kg BW, PO, q8h, ferrous sulfate (Ferrous sulfate; Plus Pharma, Commack, New York, New York, USA), 8 mg/kg BW, PO, q24h, amoxicillin-clavulanic acid, a transdermal fentanyl patch (50 µg/h) and famotidine (Famotidine; Baxter Healthcare), 1 mg/kg BW, PO, q12h.
respectively. A focal urinary bladder ultrasound revealed a centrally thickened bladder wall with minimal luminal debris. Urine via cystocentesis was cloudy with a pH of 5.0 (RR: 5.5 to 7.0), and hematuria (RBC > 50, RR: 0 to 3 RBC/hpf).

One month after surgery, the owner reported no evidence of gross hematuria or other clinical abnormalities and the PCV and TS were normal at 44% and 70 g/L. Urinalysis via cystocentesis disclosed grossly cloudy urine, and hematuria (21 to 50 RBC/hpf). The dog was administered yunnan baiyao (Yunnan baiyao; Activeherb Technology, San Diego, California, USA), 0.25 g, PO, q12h for persistent microscopic hematuria (21 to 50 RBC/hpf). The dog was administered yunnan baiyao (frequency increased to 0.25 g PO, q8h) and methenamine (Urex; Vatring Pharmaceuticals, Wytheville Virginia, USA) (10 mg/kg BW, PO, q6h). Gross hematuria, urethral obstruction, and blood loss anemia persisted for the next 24 h. The creatinine was increased (309 mmol/L) suspected secondary to a right ureteral obstruction evident on repeat urinary tract ultrasound. The dog was humanely euthanized with pentobarbital (Fatal Plus; Vertex Pharmaceutical, Cambridge, Massachusetts, USA), 1 mL/5 kg BW, IV, due to right renal hemorrhage that resulted in ureteral obstruction and subsequent azotemia. The right kidney was not obtained for histopathology.

**Discussion**

This report describes surgically assisted instillation of aseptically filtered 0.5% silver nitrate solution into a renal pelvis with gross hemorrhage via a catheterized ureter. Following instillation, the ureter was manually occluded to ensure contact time and subsequent eschar formation. This procedure is different from protocols reported in the human literature which describe installation of a 0.25% to 1.0% solution through a ureteral catheter placed with cystoscopic guidance. The catheter remains in situ up to 3 d to allow for repeated instillations (12–14). Fluoroscopic-guided renal pelvic installation of silver nitrate has been performed in veterinary medicine with reported success and minimal complications (15).

Silver nitrate is a cauterizing agent that coagulates cellular protein resulting in an eschar (12) and cessation of hemorrhage. Installation of silver nitrate into the urogenital tract has been reported in the human literature for treatment of renal hematuria, bladder hemorrhage, and chyluria (12,13). Reported complications include flank pain, nausea, vomiting, hematuria, acute renal and hepatic failure, and necrotizing ureteritis but are uncommon (12–14).

The dog in this case exhibited intermittent bleeding with its severity resulting in a clinical anemia requiring multiple transfusions. Two cystoscopic procedures and a third cystotomy were initially required to confirm the kidneys as the source of the hemorrhage. The left kidney was determined to be the primary source of hemorrhage, urinary blood clots, and clinical anemia on the initial and subsequent evaluations; however, gross hemorrhage was visualized from the right ureter during cystoscopy prior to the patient’s first treatment but was not repeatable at that time or on multiple gross examinations. An intra-operative urinalysis at the first treatment time revealed microscopic hematuria. The combination of these findings is indicative of intermittent hemorrhage from the right kidney. The possibility of catheter-induced trauma accounting for the microscopic hematuria exists but is thought to be less likely given the previous cystoscopic finding of gross hemorrhage. Given the bilateral...
involvement on initial evaluation and concern for preservation of renal function, nephrectomy was not considered a viable treatment option. Both kidneys were not treated with silver nitrate simultaneously because there was concern that the silver nitrate could induce acute renal injury. Instead, the left kidney was chosen for treatment because that is the side that had gross hematuria during surgical exploration.

Ten months following the procedure, gross hematuria and blood loss anemia recurred. The left renal pelvic hematoma was suggestive that the left kidney was again the primary source of hemorrhage, and instillation of a 0.5% silver nitrate solution was repeated on the left side only. A urinalysis was not obtained from the right kidney to monitor for microscopic hematuria and the urine was grossly normal in appearance.

The transient response to the second instillation of silver nitrate could be a result of inadequate contact time and lack of eschar formation due to the large blood clot in the renal pelvis that could not be removed. Alternatively the presumed left-sided persistent bleeding could have resulted from the histologically confirmed subacute pyelonephritis rather than a recurrence of the idiopathic hemorrhage. The pyelonephritis was either bacterial, secondary to contamination during the recent surgical procedure, or an expected sterile inflammatory reaction to the silver nitrate solution. Urine was not cultured prior to instillation and it is possible that bacteria smaller than the size restriction of the nylon membrane present in the silver nitrate solution could have been introduced during the procedure.

Gross examination of urine exiting the ureteral catheter at the time of second silver nitrate instillation and left-sided nephrectomy failed to reveal gross hemorrhage from either kidney. Given the known bilateral involvement as evident by gross hemorrhage visualized on cystoscopy prior to the first treatment and documented on urinalysis, it is plausible that the source of the continued bleeding was actually the right kidney that was not treated at any time with the silver nitrate solution. Due to the lack of knowledge regarding the long-term effects and safety of the silver nitrate solution and previous cessation of hemorrhage with unilateral treatment, bilateral simultaneous instillation was not considered to be a safe treatment option.

The dog was administered a urinary antiseptic agent, methenamine, prior to euthanasia. This compound is hydrolyzed to formaldehyde in the urine which may have co-agulation properties. The dog received the medication for less than 24 h prior to euthanasia and its efficacy could not be evaluated.

This case report demonstrates the importance of alternative treatment options for cases of idiopathic renal hematuria. As in this report, previous cases of bilateral renal bleeding resulted in death or euthanasia due to the lack of treatment options once a nephrectomy has been performed. The initial response to the chemical cauterization with silver nitrate was favorable and resulted in 10 mo without clinical signs or anemia.

The authors believe that the yunnan baiyao administered did not contribute to the dog’s 10-month interval without gross hematuria. Following the initial treatment the dog was free of gross hematuria for 1 month before the yunnan baiyao was started by the referring veterinarian. The medication was administered for persistent microscopic hematuria, which was documented to be occurring from the untreated right kidney and did not resolve on subsequent urinalyses. Additionally this medication at increased frequency failed to resolve right-sided gross hemorrhage following the dogs left nephrectomy. The efficacy of this agent in the treatment of idiopathic renal hematuria is unknown. Its contribution to controlling or preventing recurrence of gross hemorrhage after the initial treatment cannot be determined in this case.

The recurrence of blood loss anemia and documented blood clots in bladder and ureters bolsters the possibility that the right kidney was the source of the hemorrhage following the second silver nitrate treatment. Given the intermittent nature of the hemorrhage from either kidney and lack of grossly visualization at the time of the nephrectomy, it cannot be definitively stated that second silver nitrate treatment was unsuccessful.

Chemical cauterization with silver nitrate solution should be considered a viable option for treatment of severe idiopathic renal hematuria. This case report demonstrates resolution of clinical signs and anemia for 10 months following instillation of a 0.5% silver nitrate solution into a grossly hemorrhaging renal pelvis. The efficacy of subsequent silver nitrate treatments cannot be fully evaluated given the known bilateral involvement. Additional studies exploring the efficacy, safety, and long-term effects of renal pelvic silver nitrate instillation are warranted.

References